Get alerted when Policy 4723-A changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy governs prior authorization and continuation of Medicare Part B coverage for Jemperli in adults with specified endometrial and other solid tumors, including FDA-approved and compendial indications. Coverage requires the applicable disease, biomarker, prior-treatment, disease-status, and regimen criteria described in the policy.
Policy Summary
PayerClover Health
PolicyStandard Medicare Part B Management Jemperli
Policy CodePolicy 4723-A
Change TypeNo material change
Effective DateNot specified
Next Review DateNot specified
Key ActionSubmit prior authorization requests with documentation that the requested Jemperli use meets all applicable approval criteria.
No material clinical or coverage changes in this revision.
12 monthsStandard authorization duration
36 monthsEndometrial therapy limit after combination treatment
MSI-H/dMMRPrimary biomarker requirement
POLE/POLD1Additional biomarker for selected indications
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
2
FDA-approved endometrial treatment approaches
12 monthsContinuation authorization period
Covered Indications and Authorization Criteria
Endometrial cancer
Authorization of 12 months may be granted when either of the following endometrial cancer pathways is met.
Endometrial cancer pathways
Single-agent recurrent or advanced endometrial cancer: Jemperli is used as a single agent for MSI-H or dMMR recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
Combination therapy for advanced or recurrent endometrial carcinoma: Jemperli is used with carboplatin and paclitaxel for stage III-IV or recurrent endometrial carcinoma, followed by Jemperli monotherapy.Up to 6 combination doses
Solid tumors
Authorization of 12 months may be granted.
Solid tumors: Jemperli is used as a single agent for recurrent or advanced dMMR solid tumors that have progressed on or following prior treatment and for which there are no satisfactory alternative treatment options.
Breast cancer
Authorization of 12 months may be granted.
Breast cancer: Jemperli is used as a single agent for breast cancer with no response to preoperative systemic therapy, or recurrent unresectable or stage IV disease, when the tumor is MSI-H or dMMR, has progressed on or following prior treatment, and there are no satisfactory alternative treatment options.
Colorectal cancer
Authorization of 12 months may be granted.
Colorectal cancer: Jemperli is used as a single agent for subsequent treatment of colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma, with an MSI-H, dMMR, or POLE/POLD1 tumor.
Esophageal, esophagogastric junction, and gastric cancer
Authorization of 12 months may be granted when all criteria are met.
Esophageal, esophagogastric junction, or gastric cancer: The requested medication is used as a single agent; as palliative therapy for a patient who is not a surgical candidate or has unresectable locally advanced, recurrent, or metastatic disease; and for an MSI-H or dMMR tumor.
Additional esophageal and gastric pathways
Additional gastric and esophageal pathways are covered for 12 months.
Additional esophageal or gastric pathways
Early-stage or surgically unresectable locoregional gastric adenocarcinoma: Gastric adenocarcinoma is MSI-H or dMMR in a member with early-stage disease or who is medically fit for surgery with surgically unresectable locoregional disease.
Induction therapy for dysphagia: Jemperli is used as single-agent induction therapy to relieve dysphagia in a surgical candidate with esophageal or esophagogastric junction cancer that is MSI-H or dMMR.
Occult primary cancer
Authorization of 12 months may be granted.
Occult primary cancer: Jemperli is used as a single agent for MSI-H or dMMR occult primary cancer that has progressed on or following prior treatment and has no satisfactory alternative treatment options.
Ovarian cancer
Authorization of 12 months may be granted.
Ovarian cancer: Jemperli is used as a single agent for recurrent, persistent, or advanced MSI-H or dMMR epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, carcinosarcoma, clear cell carcinoma of the ovary, mucinous carcinoma of the ovary, grade 1 endometrioid carcinoma, or low-grade serous carcinoma/ovarian borderline epithelial tumors.
Small bowel adenocarcinoma
Authorization of 12 months may be granted.
Small bowel adenocarcinoma: Jemperli is used as a single agent for advanced or metastatic small bowel adenocarcinoma with an MSI-H, dMMR, or POLE/POLD1 tumor, and the member has had no previous treatment with a checkpoint inhibitor.
Ampullary adenocarcinoma
Authorization of 12 months may be granted.
Ampullary adenocarcinoma: Jemperli is used as a single agent for subsequent treatment of recurrent or advanced MSI-H or dMMR ampullary adenocarcinoma that has progressed on or following prior treatment and has no satisfactory alternative treatment options.
Biliary tract cancers
Authorization of 12 months may be granted.
Biliary tract cancers: Jemperli is used as a single agent for subsequent treatment of unresectable, resected gross residual (R2), or metastatic gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma that is MSI-H and/or dMMR, with no previous checkpoint inhibitor treatment and no satisfactory alternative treatment options.
Hepatocellular carcinoma
Authorization of 12 months may be granted.
Hepatocellular carcinoma: Jemperli is used as a single agent for subsequent treatment of MSI-H and/or dMMR hepatocellular carcinoma, with no previous checkpoint inhibitor treatment and no satisfactory alternative treatment options.
Pancreatic adenocarcinoma
Authorization of 12 months may be granted.
Pancreatic adenocarcinoma: Jemperli is used as a single agent for recurrent, locally advanced, or metastatic MSI-H or dMMR pancreatic adenocarcinoma.
Continuation therapy
Authorization for continuation of therapy may be granted for 12 months when all criteria are met.
Continuation of therapy: The member is currently receiving Jemperli; the medication is being used for an indication listed in the coverage criteria; and the member is receiving benefit from therapy, defined as no unacceptable toxicity and no disease progression on the current regimen.
Monotherapy after combination use with carboplatin and paclitaxel for endometrial carcinoma is not approved beyond 36 months total therapy.
Continuation Therapy
Continuation authorization may be granted for 12 months when all of the following criteria are met.
Continuation of therapy
Current treatment: The member is currently receiving therapy with the requested medication.
Covered indication: The requested medication is being used to treat an indication listed in the coverage criteria section.
Clinical benefit: The member is receiving benefit from therapy.
Benefit is defined as no evidence of unacceptable toxicity while on the current regimen and no evidence of disease progression while on the current regimen.
Jemperli (dostarlimab-gxly) is an antineoplastic therapy used as a single agent or, for selected advanced or recurrent endometrial carcinoma, after combination treatment with carboplatin and paclitaxel. In the combination regimen, Jemperli is continued as monotherapy; continuation coverage requires that the member is receiving benefit from therapy, with no unacceptable toxicity or disease progression.
For endometrial carcinoma, Jemperli monotherapy following combination use with carboplatin and paclitaxel is subject to a 36-month total therapy limit. Treatment beyond 36 months of total therapy is not approved.
Authorization, Documentation, and Denial Rules
Prior Authorization
Initial Authorization Required
Prior authorization is required for Jemperli, and the requested use must be an FDA-approved indication or a listed compendial use. Coverage is available only when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.
Submit the diagnosis and clinical information supporting the requested indication.
For indications not listed in the policy criteria, include supporting evidence from Medicare-approved compendia.
Prior Authorization
Twelve-Month Initial Authorization
An initial authorization may be granted for 12 months when the requested use meets the applicable cancer-specific criteria below.
Endometrial cancer: As monotherapy for MSI-H or dMMR recurrent or advanced disease that progressed on or following prior platinum-containing therapy; or in combination with carboplatin and paclitaxel for stage III-IV or recurrent disease, followed by Jemperli monotherapy after up to 6 combination doses.
Solid tumors: As monotherapy for recurrent or advanced dMMR solid tumors that progressed on or following prior treatment and have no satisfactory alternative treatment options.
Therapy Overview
Jemperli (dostarlimab-gxly) is an antineoplastic therapy used as monotherapy across specified cancer indications and in combination with carboplatin and paclitaxel for selected advanced or recurrent endometrial carcinoma. The combination regimen is followed by Jemperli monotherapy. For continuation, the member must be receiving the medication for a covered indication and benefiting from treatment, defined as no unacceptable toxicity and no disease progression on the current regimen.
Policy Terms and Clinical Definitions
MSI-H
DefinitionA tumor characterized by high microsatellite instability, as confirmed by an applicable laboratory test.
dMMR
DefinitionA tumor with deficient mismatch repair, as confirmed by an applicable laboratory test.
POLE/POLD1
DefinitionTumor status involving polymerase epsilon or polymerase delta alterations, where applicable to the requested indication.
Benefit from therapy
Treatment-Line Requirements
First-line
The first-line treatment designation applies when the following criterion is met.
First-line treatment: Jemperli is combined with carboplatin and paclitaxel for stage III-IV or recurrent endometrial carcinoma, followed by Jemperli monotherapy.Up to 6 combination doses
Salvage
The salvage treatment designation applies when the following criterion is met.
Salvage treatment: The tumor has progressed on or following prior treatment, or the request is for subsequent treatment, as specified by the applicable cancer-specific criteria.
Required Tumor Biomarker Status
MSI-H
MSI-H requirementHigh microsatellite instability confirmed by an applicable laboratory report.
dMMR
dMMR requirementMismatch repair deficiency confirmed by an applicable laboratory report.
POLE/POLD1
POLE/POLD1 requirementPolymerase epsilon/delta tumor status confirmed by a laboratory report, where applicable.
Covered Treatment Regimens
Regimen
Covered indication
Coverage
Jemperli in combination with carboplatin and paclitaxel for up to 6 combination doses, followed by Jemperli as a single agent
Stage III-IV or recurrent endometrial carcinoma
Covered
Covered tumor type or indication
Biomarker and clinical requirements
Coverage
Recurrent or advanced endometrial cancer
MSI-H or dMMR; progressed on or following prior treatment with a platinum-containing regimen
Covered
Recurrent or advanced solid tumors
dMMR; progressed on or following prior treatment; no satisfactory alternative treatment options
Covered
Breast cancer
MSI-H or dMMR; no response to preoperative systemic therapy, or recurrent unresectable or stage IV disease; progressed on or following prior treatment; no satisfactory alternative treatment options
Covered
Colorectal cancer, including appendiceal and anal adenocarcinoma
MSI-H, dMMR, or POLE/POLD1 tumor; subsequent treatment
Covered
Esophageal, esophagogastric junction, or gastric cancer
MSI-H or dMMR; single-agent use as palliative therapy for unresectable locally advanced, recurrent, or metastatic disease, or when the patient is not a surgical candidate
Covered
Occult primary cancer
MSI-H or dMMR; progressed on or following prior treatment; no satisfactory alternative treatment options
Covered
Ovarian, fallopian tube, primary peritoneal, and specified ovarian tumors
MSI-H or dMMR; recurrent, persistent, or advanced disease
Covered
Small bowel adenocarcinoma
MSI-H, dMMR, or POLE/POLD1; advanced or metastatic disease; no previous treatment with a checkpoint inhibitor
Covered
Ampullary adenocarcinoma
MSI-H or dMMR; recurrent or advanced disease; progressed on or following prior treatment; no satisfactory alternative treatment options
Covered
Biliary tract cancers
MSI-H and/or dMMR; unresectable, resected gross residual (R2), or metastatic gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma; no previous checkpoint inhibitor treatment; no satisfactory alternative treatment options
Covered
Hepatocellular carcinoma
MSI-H and/or dMMR; subsequent treatment; no previous checkpoint inhibitor treatment; no satisfactory alternative treatment options
Covered
Pancreatic adenocarcinoma
MSI-H or dMMR; recurrent, locally advanced, or metastatic disease
Covered
Regimen
Covered indication
Therapy limit
Coverage
Combination use with carboplatin and paclitaxel followed by Jemperli monotherapy
Endometrial carcinoma
Jemperli monotherapy after the combination regimen is not approved beyond 36 months of total therapy
Covered with limit
Policy Summary
PayerClover Health
PolicyStandard Medicare Part B Management Jemperli
Policy CodePolicy 4723-A
Change TypeNo material change
Effective DateNot specified
Next Review DateNot specified
Key ActionSubmit prior authorization requests with documentation that the requested Jemperli use meets all applicable approval criteria.
Breast cancer: As monotherapy for no response to preoperative systemic therapy, or recurrent unresectable or stage IV MSI-H/dMMR disease that progressed on or following prior treatment with no satisfactory alternative treatment options.
Esophageal, esophagogastric junction, and gastric cancer: As monotherapy for qualifying MSI-H/dMMR disease, including palliative treatment for unresectable or advanced disease, qualifying unresectable locoregional gastric disease, or induction therapy to relieve dysphagia in eligible surgical candidates.
Occult primary cancer: As monotherapy for MSI-H/dMMR disease that progressed on or following prior treatment and has no satisfactory alternative treatment options.
Ovarian cancer: As monotherapy for recurrent, persistent, or advanced MSI-H/dMMR epithelial ovarian, fallopian tube, primary peritoneal, carcinosarcoma, clear cell, mucinous, grade 1 endometrioid, or low-grade serous/borderline epithelial tumors.
Small bowel adenocarcinoma: As monotherapy for advanced or metastatic MSI-H, dMMR, or POLE/POLD1 tumors with no previous checkpoint inhibitor treatment.
Ampullary adenocarcinoma: As monotherapy for subsequent treatment of recurrent or advanced MSI-H/dMMR disease that progressed on or following prior treatment and has no satisfactory alternative treatment options.
Biliary tract cancers: As monotherapy for subsequent treatment of qualifying unresectable, R2 residual, or metastatic gallbladder cancer or cholangiocarcinoma, with no previous checkpoint inhibitor treatment and no satisfactory alternative treatment options.
Hepatocellular carcinoma: As monotherapy for subsequent treatment of MSI-H/dMMR disease, with no previous checkpoint inhibitor treatment and no satisfactory alternative treatment options.
Pancreatic adenocarcinoma: As monotherapy for recurrent, locally advanced, or metastatic MSI-H/dMMR disease.
Prior Authorization
Continuation Authorization
For continuation requests, the member must be currently receiving Jemperli. Authorization may be granted for 12 months when all continuation requirements are met.
The requested medication is being continued without interruption.
The medication is being used for an indication listed in the coverage criteria.
Unsupported block type: documentation
Documentation Required
Tumor Biomarker Laboratory Report
For all initial requests, maintain and provide upon request a laboratory report documenting the tumor biomarker status when applicable.
For an indication not listed in the policy criteria, the submission must include supporting evidence from Medicare-approved compendia. Such requests are assessed individually.
Include the compendium name and the evidence supporting Jemperli for the requested indication.
Denial Risk
Failure to Meet Indication Criteria
An initial request may be denied when the requested use is not an FDA-approved indication or listed compendial use, or when the applicable cancer-specific coverage criteria are not met.
The submitted indication does not match a covered policy indication.
Required disease stage, biomarker status, prior treatment, treatment setting, or alternative-treatment criteria are not documented.
Required Medicare-approved compendia support is absent for an unlisted indication.
Denial Risk
Continuation Criteria Not Met
A continuation request may be denied when the member is not currently receiving Jemperli, the medication is not being used for a listed indication, or there is no documented benefit from the current regimen.
Unacceptable toxicity is present on the current regimen.
Disease progression is documented while receiving the current regimen.
Required continuation documentation is not provided.
Denial Risk
Endometrial Therapy Duration Limit
Treatment with Jemperli for endometrial carcinoma is subject to a 36-month total therapy limit when monotherapy follows combination treatment with carboplatin and paclitaxel.
Count combination and subsequent monotherapy toward the total treatment duration.
Do not request or administer therapy beyond 36 months total.
Denial Risk
Prior Checkpoint Inhibitor Exposure
For selected tumor types, Jemperli is restricted to members with no previous checkpoint inhibitor treatment.
Small bowel adenocarcinoma: no previous checkpoint inhibitor treatment.
Biliary tract cancers: no previous checkpoint inhibitor treatment.
Hepatocellular carcinoma: no previous checkpoint inhibitor treatment.
Denial Risk
Endometrial Carcinoma Monotherapy Duration Limit
Jemperli monotherapy after combination treatment with carboplatin and paclitaxel for endometrial carcinoma will not be approved beyond 36 months of total therapy.
The 36-month limit applies to the combined duration of carboplatin/paclitaxel therapy and subsequent Jemperli monotherapy.
Benefit from therapy
No evidence of unacceptable toxicity while on the current regimen and no evidence of disease progression while on the current regimen.
Benefit from therapy
Continuation requirementThe member must be receiving benefit from therapy on the current regimen, defined as no evidence of unacceptable toxicity and no evidence of disease progression.